<HTML lang="en" dir="ltr" class="client-nojs">
<style type="text/css">
A:before { content:' '; } 
A:after { content:' '; } 
SPAN:before { content:' '; } 
SPAN:after { content:' '; } 
</style>
<BODY class="mediawiki ltr sitedir-ltr ns-0 ns-subject page-Team_UNA_Honduras_entrepreneurship_html skin-igem action-view"><DIV id="globalWrapper"><DIV id="content" class="mw-body" role="main"><H1 id="firstHeading" class="firstHeading"><SPAN dir="auto">Team:UNA Honduras/entrepreneurship.html</SPAN></H1><DIV id="bodyContent"><DIV id="mw-content-text" lang="en" dir="ltr" class="mw-content-ltr"><DIV id="art-main"><DIV class="art-sheet clearfix"><DIV class="art-layout-wrapper"><DIV class="art-content-layout"><DIV class="art-content-layout-row"><DIV class="art-layout-cell art-sidebar1"><DIV class="art-vmenublock clearfix"><DIV class="art-vmenublockheader"><H3 class="t">Menu</H3></DIV><DIV class="art-vmenublockcontent"><UL class="art-vmenu"><LI><A href="https://2015.igem.org/Team:UNA_Honduras" class="active">HOME</A></LI><LI><A href="https://2015.igem.org/Team:UNA_Honduras/team.html">TEAM</A></LI><LI><A href="https://2015.igem.org/Team:UNA_Honduras/project.html">PROJECT</A></LI><LI><A href="https://2015.igem.org/Team:UNA_Honduras/description.html">DESCRIPTION</A></LI><LI><A href="https://2015.igem.org/Team:UNA_Honduras/immunology-of-dengue.html">IMMUNOLOGY OF DENGUE</A></LI><LI><A href="https://2015.igem.org/Team:UNA_Honduras/experiments-and-protocols.html">EXPERIMENTS AND PROTOCOLS</A></LI><LI><A href="https://2015.igem.org/Team:UNA_Honduras/results.html">RESULTS</A></LI></UL><LI><A href="https://2015.igem.org/Team:UNA_Honduras/parts.html">PARTS</A></LI><LI><A href="https://2015.igem.org/Team:UNA_Honduras/notebook.html">NOTEBOOK</A></LI><LI><A href="https://2015.igem.org/Team:UNA_Honduras/attributions.html">ATTRIBUTIONS</A></LI><LI><A href="https://2015.igem.org/Team:UNA_Honduras/collaborations.html">COLLABORATIONS</A></LI><LI><A href="https://2015.igem.org/Team:UNA_Honduras/human-practices.html">HUMAN PRACTICES</A></LI><LI><A href="https://2015.igem.org/Team:UNA_Honduras/public-outreach.html">PUBLIC OUTREACH</A></LI><LI><A href="https://2015.igem.org/Team:UNA_Honduras/laws-regulation.html">LAWS &amp; REGULATION</A></LI><LI><A href="https://2015.igem.org/Team:UNA_Honduras/ethics.html">ETHICS</A></LI><LI><A href="https://2015.igem.org/Team:UNA_Honduras/media-coverage.html">MEDIA COVERAGE</A></LI><LI><A href="https://2015.igem.org/Team:UNA_Honduras/safety.html">SAFETY</A></LI><LI><A href="https://2015.igem.org/Team:UNA_Honduras/entrepreneurship.html">ENTREPRENEURSHIP</A></LI><LI><A href="https://2015.igem.org/Team:UNA_Honduras/gallery.html">GALLERY</A></LI><LI><A href="https://2015.igem.org/Team:UNA_Honduras/references.html">REFERENCES</A></LI></DIV></DIV></DIV><DIV class="art-layout-cell art-content"><ARTICLE class="art-post art-article"><DIV class="art-postmetadataheader"><H2 class="art-postheader">Entrepreneurship</H2></DIV><DIV class="art-postcontent art-postcontent-0 clearfix"><P class="MsoNormal" style="text-align: justify;"><SPAN lang="EN-US" style="font-size: 12pt; line-height: 106%;">Dengue virus has been treated in a
corrective way taking the effects it produces in the body until its natural
immune reaction takes place to get rid of the pain, particular details as
hematocritos, plaquetes and white globules are some tests taken in the
corrective handle of the disease. It is important to know that there are four
serotypes involved in this virus (A, B, C, and D), which serotype B and
serotype D are the more predominant in Honduras.</SPAN></P><P class="MsoNormal" style="text-align: justify;"><SPAN lang="EN-US" style="font-size: 12pt; line-height: 106%;">A second infection with a different
serotype virus causes a cross immunological reaction called “Dengue
Hemorragico” (Hemorrhagic Dengue) due to its hemorrhagic (internal and
external) symptoms which are highly lethal.</SPAN></P><P class="MsoNormal" style="text-align: justify;"><SPAN lang="EN-US" style="font-size: 12pt; line-height: 106%;">On year 2010 there were 39 million
cases of Dengue disease in the world. There were 66,814 cases reported in
Honduras according to the Weekly Epidemiological Telegram of the Honduras
Health Secretariat, Vector General Direction.</SPAN></P><P class="MsoNormal" style="text-align: justify;"><SPAN lang="EN-US" style="font-size: 12pt; line-height: 106%;">Based on this statistics the
IGEM-UNAH team is proposed to create a protein that awake the body immune
response to the 4 serotypes to avoid the cross reaction previously mentioned.</SPAN></P><P class="MsoNormal" style="text-align: justify;"><SPAN lang="EN-US" style="font-size: 12pt; line-height: 106%;">To obtain this protein, the Synthetic
Biology was used as a prime process through incorporation of a plasmid in a
bacteria (E. Coli) in order to be replicated and getting this way the
previously studied protein where four Dengue virus serotypes epitopes were
incorporated in the plasmids to be inserted in the bacteria.</SPAN></P><P class="MsoNormal" style="text-align: justify;"><SPAN lang="EN-US" style="font-size: 12pt; line-height: 106%;">This process took several months of
hard team work in several ways like conceptualization (virology, immunology,
bacteriology, molecular bacteriology, etc.) and the laboratory analysis and
other to get that the searched protein could comply with quality standards as
well as the goal for which it was designed.</SPAN></P><P class="MsoNormal" style="text-align: justify;"><SPAN lang="EN-US" style="font-size: 12pt; line-height: 106%;">After lab tests, redesigns and other
the process was purified and systemized to obtain easy replication and of
course, the best on obtaining the protein.</SPAN></P><P class="MsoNormal" style="text-align: justify;"><SPAN lang="EN-US" style="font-size: 12pt; line-height: 106%;">The process to obtain the protein is
in process to be incorporated to the International Patents System (PCT) being
this the main product to sell within the business plan. Very important is to
mention that PCT has under its registration no protein obtained under the
Synthetic Biology process with the purpose that our product offers.</SPAN></P><P class="MsoNormal" style="text-align: justify;"><SPAN lang="EN-US" style="font-size: 12pt; line-height: 106%;">Market that our product search is
pharmacies that can reproduce the process and purify the protein to obtain the
Dengue vaccine. Knowing the occurrence of this virus disease in Honduras, Latin
America and the world we assure buyers. Another way to market this product is
to work with laboratories interested in Dengue vaccine production.</SPAN></P><P class="MsoNormal" style="text-align: justify;"><SPAN lang="EN-US" style="font-size: 12pt; line-height: 106%;">There are two ways to sell our
product: selling the patented product protocol to obtain the protein to control
Dengue and the other is create an investment oriented to the final vaccine
elaboration.</SPAN></P><P class="MsoNormal" style="text-align: justify;"><SPAN lang="EN-US" style="font-size: 12pt; line-height: 106%;">According to these two selling
possibilities there are many that can be taken as business opportunities such
as:</SPAN></P><P class="MsoNormal" style="text-align: justify;"><SPAN lang="EN-US" style="font-size: 12pt; line-height: 106%;">1.- Protocol to obtain the protein is
already elaborated which reduces the vaccine elaboration time.</SPAN></P><P class="MsoNormal" style="text-align: justify;"><SPAN lang="EN-US" style="font-size: 12pt; line-height: 106%;">2.- IGEM-UNAH team and the Honduras
Science Technology and Innovation Institute IHCIETI have the experience  to work on the Synthetic Biology to obtain
the final vaccine.</SPAN></P><P class="MsoNormal" style="text-align: justify;"><SPAN lang="EN-US" style="font-size: 12pt; line-height: 106%;">3.- Both IGEM-UNAH and IHCIETI are
well known organizations with high ranks of Synthetic Biology in our country.</SPAN></P><P class="MsoNormal" style="text-align: justify;"><SPAN lang="EN-US" style="font-size: 12pt; line-height: 106%;">4.- The need of vaccine to combat
Dengue, that does not exists, and that is needed worldwide in the tropic and
subtropic is a great opportunity to market the product and great possibility of
international business.</SPAN></P><P class="MsoNormal" style="text-align: justify;"><SPAN lang="EN-US" style="font-size: 12pt; line-height: 106%;">Nevertheless, there are some risks
that can affect our product such as</SPAN></P><P class="MsoNormal" style="text-align: justify;"><SPAN lang="EN-US" style="font-size: 12pt; line-height: 106%;">1.- Purification, analysis,
serological tests and others could be high in time and could increase the
elaboration costs.</SPAN></P><P class="MsoNormal" style="text-align: justify;"><SPAN lang="EN-US" style="font-size: 12pt; line-height: 106%;">2.- Economical costs of the vaccine
elaboration.</SPAN></P><P class="MsoNormal" style="text-align: justify;"><SPAN lang="EN-US" style="font-size: 12pt; line-height: 106%;">3.- Non desired reaction to the
vaccine by the patient. </SPAN></P><SPAN lang="EN-US" style="font-size: 12pt; line-height: 106%; font-family: inherit; color: rgb(33, 33, 33);">However , taking into account opportunities and
risks, it is clear that our product is quality and has great business potential
both locally and internationally</SPAN></DIV></ARTICLE></DIV></DIV></DIV></DIV></DIV><P class="art-page-footer"><SPAN id="art-footnote-links">Designed by <A href="www.bluemas.com" target="_blank">Blue+</A>.</SPAN></P></DIV></DIV></DIV></DIV></DIV></BODY></HTML>